BACKGROUND: Vascular endothelial growth factor (VEGF)-B activates cytoprotective/antiapoptotic and minimally angiogenic mechanisms via VEGF receptors. Therefore, VEGF-B might be an ideal candidate for the treatment of dilated cardiomyopathy, which displays modest microvascular rarefaction and increased rate of apoptosis. OBJECTIVES: This study evaluated VEGF-B gene therapy in a canine model of tachypacing-induced dilated cardiomyopathy. METHODS: Chronically instrumented dogs underwent cardiac tachypacing for 28 days. Adeno-associated virus serotype 9 viral vectors carrying VEGF-B167 genes were infused intracoronarily at the beginning of the pacing protocol or during compensated heart failure. Moreover, we tested a novel VEGF-B167 transgene controlled by the atrial natriuretic factor promoter. RESULTS: Compared with control subjects, VEGF-B167 markedly preserved diastolic and contractile function and attenuated ventricular chamber remodeling, halting the progression from compensated to decompensated heart failure. Atrial natriuretic factor-VEGF-B167 expression was low in normally functioning hearts and stimulated by cardiac pacing; it thus functioned as an ideal therapeutic transgene, active only under pathological conditions. CONCLUSIONS: Our results, obtained with a standard technique of interventional cardiology in a clinically relevant animal model, support VEGF-B167 gene transfer as an affordable and effective new therapy for nonischemic heart failure.
BACKGROUND:Vascular endothelial growth factor (VEGF)-B activates cytoprotective/antiapoptotic and minimally angiogenic mechanisms via VEGF receptors. Therefore, VEGF-B might be an ideal candidate for the treatment of dilated cardiomyopathy, which displays modest microvascular rarefaction and increased rate of apoptosis. OBJECTIVES: This study evaluated VEGF-B gene therapy in a canine model of tachypacing-induced dilated cardiomyopathy. METHODS: Chronically instrumented dogs underwent cardiac tachypacing for 28 days. Adeno-associated virus serotype 9 viral vectors carrying VEGF-B167 genes were infused intracoronarily at the beginning of the pacing protocol or during compensated heart failure. Moreover, we tested a novel VEGF-B167 transgene controlled by the atrial natriuretic factor promoter. RESULTS: Compared with control subjects, VEGF-B167 markedly preserved diastolic and contractile function and attenuated ventricular chamber remodeling, halting the progression from compensated to decompensated heart failure. Atrial natriuretic factor-VEGF-B167 expression was low in normally functioning hearts and stimulated by cardiac pacing; it thus functioned as an ideal therapeutic transgene, active only under pathological conditions. CONCLUSIONS: Our results, obtained with a standard technique of interventional cardiology in a clinically relevant animal model, support VEGF-B167 gene transfer as an affordable and effective new therapy for nonischemic heart failure.
Authors: Christina A Pacak; Cathryn S Mah; Bijoy D Thattaliyath; Thomas J Conlon; Melissa A Lewis; Denise E Cloutier; Irene Zolotukhin; Alice F Tarantal; Barry J Byrne Journal: Circ Res Date: 2006-07-27 Impact factor: 17.367
Authors: Wolfgang Rottbauer; Steffen Just; Georgia Wessels; Nicole Trano; Patrick Most; Hugo A Katus; Mark C Fishman Journal: Genes Dev Date: 2005-07-01 Impact factor: 11.361
Authors: A Saraste; K Pulkki; M Kallajoki; P Heikkilä; P Laine; S Mattila; M S Nieminen; M Parvinen; L M Voipio-Pulkki Journal: Eur J Clin Invest Date: 1999-05 Impact factor: 4.686
Authors: M Meyer; M Clauss; A Lepple-Wienhues; J Waltenberger; H G Augustin; M Ziche; C Lanz; M Büttner; H J Rziha; C Dehio Journal: EMBO J Date: 1999-01-15 Impact factor: 11.598
Authors: Minoru Satoh; Christian M Matter; Hisakazu Ogita; Kyosuke Takeshita; Chao-Yung Wang; Gerald W Dorn; James K Liao Journal: Circulation Date: 2007-06-11 Impact factor: 29.690
Authors: Mitsuru Seki; Jeffery C Powers; Sonomi Maruyama; Maria A Zuriaga; Chia-Ling Wu; Clara Kurishima; Lydia Kim; Jesse Johnson; Anthony Poidomani; Tao Wang; Eric Muñoz; Sudarsan Rajan; Joon Y Park; Kenneth Walsh; Fabio A Recchia Journal: Circ Heart Fail Date: 2018-01 Impact factor: 8.790
Authors: Mitsuru Seki; Ryan LaCanna; Jeffery C Powers; Christine Vrakas; Fang Liu; Remus Berretta; Geena Chacko; John Holten; Pooja Jadiya; Tao Wang; Jeffery S Arkles; Joshua M Copper; Steven R Houser; Jianhe Huang; Vickas V Patel; Fabio A Recchia Journal: J Pharmacol Exp Ther Date: 2016-06-27 Impact factor: 4.030
Authors: Markus Räsänen; Joni Degerman; Tuuli A Nissinen; Ilkka Miinalainen; Risto Kerkelä; Antti Siltanen; Janne T Backman; Eero Mervaala; Juha J Hulmi; Riikka Kivelä; Kari Alitalo Journal: Proc Natl Acad Sci U S A Date: 2016-10-31 Impact factor: 11.205
Authors: Michael G Katz; Anthony S Fargnoli; Thomas Weber; Roger J Hajjar; Charles R Bridges Journal: Hum Gene Ther Clin Dev Date: 2017-07-19 Impact factor: 5.032